Login to Your Account



Regulatory NEWS

Despite congressional demands that CMS withdraw a controversial Part B demonstration model, the agency seems bent on finalizing the rule that would establish the nationwide experiment, possibly with some tweaks.

The Supreme Court of the United States on June 27 declined to hear the case of Sequenom v. Ariosa, which invokes the problematic law-of-nature discussion that proved decisive in a landmark case at the court.

FDA reviewers told agency advisors in briefing docs released Friday that Jardiance (empagliflozin) postmarket data show "substantial evidence" that, for certain adults with type 2 diabetes, the drug reduces the risk of cardiovascular death.

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: